Rivastigmine vs placebo
Risk for at least one adverse event per patient · Apathy in people with mild‐to‐moderate Alzheimer's disease
Rivastigmine probably leads to higher incidence of adverse events (at least one adverse event by 26 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
- OR 2.14 [1.8, 2.53]7 studies · 3587 participantsModerate